Specialties › Endocrinology Billing
Endocrinology is the most lab-intensive, device-driven, and diagnosis-specific specialty in outpatient medicine. CGM supply billing, insulin pump management codes, thyroid ultrasound interpretations, diabetes education bundles, and complex multi-hormone panel interpretations — each one a separately billable revenue stream that generalist billing teams routinely collapse into the E&M code and never charge.
The average endocrinology practice loses $220,000–$680,000 annually to missed CGM supply codes, under-coded lab interpretation panels, unbilled diabetes education services, missed insulin pump management codes, and incorrect therapeutic drug monitoring billing. A ParaMed endocrinology audit identifies every gap — at zero cost to your practice.
Established · HbA1c 8.9% · CGM prescribed + initiated · Insulin adjustment · Retinopathy screening review
T2DM with complications, multiple medication adjustments, CGM initiation
CGM receiver device supply code — separately billable from the E&M visit
Continuous glucose monitoring sensor per 30-day supply — monthly recurring DME
Individual diabetes outpatient self-management training — 30 min
HbA1c (83036) + CMP (80053) + lipid panel (80061) results interpreted
Revenue gap identified: Previous biller submitted only 99214 ($218) — missing CGM device codes, diabetes education, and lab interpretation. Correct billing = $908. Previous billing = $218. Revenue recovered per encounter: $690.
CGM devices generate recurring monthly supply revenue (A9276 sensors, A9278 receiver) separate from the office visit. Practices not billing DME supply codes lose this stream entirely.
When labs ordered by the endocrinologist are interpreted and the results directly drive clinical decisions documented in the note — the interpretation is separately billable beyond the E&M visit.
Across CGM supply codes, insulin pump management codes, diabetes education, lab interpretation, and correct E&M complexity selection — the average endocrinology encounter is under-billed by $480.
Insulin pump initiation (95249), training (95250), and management (95251) are separately billable from the office visit — generating $128–$392 per pump management encounter.
Every gland, every hormone axis, every disease category in endocrinology has its own unique billing code set — and its own specific billing errors that cost practices revenue. Click any system below to reveal the complete billing picture.
Thyroid is the highest-volume endocrine organ in outpatient practice. TSH, Free T4, Free T3, thyroid antibodies (TPO, TgAb), thyroglobulin — each lab is a separate billable code when ordered and interpreted by the endocrinologist. The most commonly lost code: the -26 modifier on ultrasound interpretations when the endocrinologist reads but doesn't perform the ultrasound.
| CPT/HCPCS | Description | Rate |
|---|---|---|
| 99215 | Complex thyroid visit — hypothyroid titration, nodule review, antibody panel | $328 |
| 76536-26 | Thyroid ultrasound interpretation — professional component onlyMost Missed | $98 |
| 10022 | FNA with ultrasound imaging guidance — thyroid nodule biopsy | $412 |
| 10021 | FNA without imaging guidance | $132 |
| 78012 | Radioactive iodine uptake — thyroid only | $148 |
| 84443 | TSH — thyroid stimulating hormone labSeparately Billable | $28 |
| 84479 | Free T4 (thyroxine) — lab interpretation | $24 |
| 86200 | TPO antibody — thyroid peroxidase | $38 |
99215 + 76536-26 + lab panel interpretation vs. E&M only
Diabetes billing has more separately billable revenue streams than any other endocrine condition: the E&M, CGM device supply codes (A9276 sensors, A9278 receiver), insulin pump management codes (95249–95251), diabetes self-management education (G0108–G0109), therapeutic continuous glucose monitoring interpretation (95251), and in-office lab interpretation. Most practices bill only the E&M — missing the DME supply billing, pump management codes, and education program billing entirely.
| CPT/HCPCS | Description | Rate |
|---|---|---|
| 99215 | T1/T2DM complex visit — insulin adjust, CGM review, complications | $328 |
| 95251 | CGM analysis, interpretation + report — monthlyOften Missed | $148 |
| 95249 | Ambulatory CGM hookup — sensor attachment, calibration | $128 |
| A9276 | CGM sensor supply — per 30 days (DME billing)DME | $184 |
| A9278 | CGM receiver/monitor supplyDME | $228 |
| G0108 | DSMES individual — 30 min sessionOften Missed | $72 |
| G0109 | DSMES group — 30 min per patient | $36 |
| 83036 | HbA1c — glycated hemoglobin lab | $22 |
99215 + 95251 + A9276 + G0108 + labs
Adrenal endocrinology generates revenue through complex dynamic testing protocols — ACTH stimulation tests, dexamethasone suppression tests, 24-hour urine collections, and adrenal vein sampling. Each component of a stimulation test is separately billable: the IV infusion, the lab draws at timed intervals, and the physician E&M for interpreting results.
| CPT | Description | Rate |
|---|---|---|
| 99215 | Complex adrenal consultation / management visit | $328 |
| 96365 | IV infusion — initial hour (cosyntropin)Often Missed | $128 |
| 82533 | Cortisol — total (per draw, × 3 in stim test) | $46/each |
| 82024 | ACTH — adrenocorticotropic hormone | $62 |
| 74178-26 | Adrenal CT interpretation — professionalMost Missed | $164 |
| 83519 | Aldosterone immunoassay | $48 |
| 82530 | Cortisol — free (24hr urine) | $58 |
| 36415 | Routine venipuncture — each draw | $12 |
99215 + infusion + 3 cortisol draws + IV access vs. E&M only
Pituitary endocrinology is the most complex billing environment in the specialty — involving multiple simultaneous hormone axes, provocative GH stimulation tests, MRI interpretation professional components, and long-term octreotide/lanreotide injection management. The GH stimulation test protocol generates 8–12 separately billable codes on a single testing day.
| CPT/HCPCS | Description | Rate |
|---|---|---|
| 99215 | Pituitary disease complex visit — multi-axis review | $328 |
| 80418 | Combined anterior pituitary panel (full)Panel Code | $288 |
| 84305 | IGF-1 (somatomedin C) — growth hormone surrogate | $62 |
| 83003 | Growth hormone — each sample (×5 in stim test)Multiple | $42/each |
| J2353 | Octreotide LAR 1mg (30mg/month = J2353×30)J-Code | $124/mg |
| 96372 | Therapeutic IM injection admin | $48 |
| 70553-26 | MRI pituitary w/ contrast — interpretationProf. Comp. | $164 |
| 84146 | Prolactin — serum | $38 |
99214 + J2353×30 + 96372 admin vs E&M only
Osteoporosis billing is deceptively complex: the DEXA scan and the interpretation (77080-26 professional component), calcium/PTH panels, bone turnover marker labs (CTX, P1NP), and intravenous bisphosphonate infusion billing (zoledronic acid — J3488). When an endocrinologist both orders and interprets the DEXA scan, the professional interpretation component is separately billable.
| CPT/HCPCS | Description | Rate |
|---|---|---|
| 77080-26 | DEXA scan — professional interpretation onlyMost Missed | $72 |
| 83970 | Parathyroid hormone — intact PTH | $58 |
| 82306 | 25-hydroxyvitamin D — serum | $44 |
| 82310 | Calcium — total serum | $18 |
| 82523 | CTX — bone resorption markerBone Marker | $48 |
| J3488 | Zoledronic acid per 1mg (5mg = ×5)Infusion Drug | $136/mg |
| 96365 | IV infusion — first hour (bisphosphonate) | $128 |
| 86849 | P1NP — procollagen bone marker | $62 |
99213 + J3488×5 + 96365 infusion vs E&M only
Reproductive endocrinology billing covers PCOS management, hypogonadism evaluation and treatment, and androgen excess disorders. The hormone panels — total and free testosterone (84402/84403), DHEA-S (82627), LH (83002), FSH (83001), estradiol (82670), SHBG (84270) — are each separately billable. Testosterone injections (J1071) plus admin code (96372) generate procedure revenue beyond the E&M that most practices don't capture.
| CPT/HCPCS | Description | Rate |
|---|---|---|
| 84402 | Testosterone — total serum | $38 |
| 84403 | Testosterone — free (equilibrium dialysis) | $48 |
| 82627 | DHEA-S — dehydroepiandrosterone sulfate | $42 |
| 82670 | Estradiol — serum | $44 |
| 83002 | LH — luteinizing hormone | $38 |
| 84270 | SHBG — sex hormone-binding globulin | $34 |
| J1071 | Testosterone cypionate per 1mg (200mg = ×200)J-Code | $0.48/mg |
| 96372 | Therapeutic IM injection admin | $48 |
99213 + J1071×200 + 96372 vs E&M only
A patient on a continuous glucose monitor with an insulin pump generates 5 distinct billing codes beyond the office visit — supply codes, monitoring codes, management codes, and education codes. Each is a separate CPT or HCPCS code. Each has a separate payment. And each is consistently missed when billing is handled by a generalist team.
Ambulatory CGM hook-up — sensor attachment, calibration, patient training
Ambulatory CGM monitoring period — 72-hour data capture for insulin pump patients
Monthly CGM data analysis, interpretation, and formal written report — recurring monthly billing
Monthly DME supply billing — sensor per 30 days + receiver device — separate from physician billing
Individual diabetes education session — per 30 minutes with CDCES, separately billable from E&M
When an endocrinologist orders a lab panel, receives the results, formally interprets the findings in the context of the clinical situation, and documents the interpretation in the medical record — that interpretation is a separately billable professional service. Not bundled into the E&M. A separate code that generates real revenue per encounter. 78% of endocrinology practices don't bill it.
TSH (84443), Free T4 (84479), Free T3 (84481), Thyroglobulin (84432), TPO antibody (86200) — each thyroid lab ordered and interpreted by the endocrinologist is a separately billable code. A full thyroid function + antibody panel generates $162 in lab codes beyond the E&M visit when all tests are individually coded and an interpretation report is documented.
HbA1c (83036), fasting glucose (82947), comprehensive metabolic panel (80053), lipid panel (80061), microalbumin (82043) — when the endocrinologist formally reviews and interprets these results in the context of the diabetes management plan, each ordered lab is a separately billable service. A complete diabetes quarterly monitoring panel generates $184+ in lab codes.
25-hydroxyvitamin D (82306), calcium total (82310), intact PTH (83970), phosphorus (84100), bone turnover markers CTX (82523) and P1NP (86849) — the complete monitoring panel for osteoporosis and metabolic bone disease generates $292 in lab codes when all individually ordered and interpreted tests are billed separately.
Endocrinology diagnoses — Type 1 diabetes, Cushing's disease, acromegaly, multiple metabolic conditions — almost universally support higher E&M complexity levels than what practices actually bill. Under-coding by even one level ($218 instead of $328 for 99215) across thousands of annual encounters is the most pervasive and consistently under-addressed revenue gap in endocrinology billing.
Patient with T2DM, HbA1c 9.2% on oral agents alone. Physician reviews CGM data for first time, decides to initiate basal insulin, orders HbA1c + CMP + lipids, discusses hypoglycemia risk, adjusts medications for renal function. New prescription drug management + independent test interpretation + chronic illness with exacerbation = moderate-to-high complexity MDM.
Established hypothyroid patient — TSH still elevated at 4.8 on 88mcg levothyroxine. Physician reviews thyroid ultrasound showing a new 8mm nodule, makes independent interpretation of ultrasound, decides to increase levothyroxine dose and schedule FNA. Independent imaging + prescription management + new concerning finding = moderate-to-high complexity MDM.
Acromegaly patient on monthly octreotide LAR. Physician reviews IGF-1 trend (still elevated), growth hormone nadir from OGTT externally, MRI pituitary report showing stable adenoma, considers dose escalation. Independent lab trends + external imaging + complex prescription drug management = clear high-complexity MDM supporting 99215, plus octreotide J-code billing.
Every in-office injectable medication in endocrinology generates three separate billable codes: (1) the drug J-code for the medication itself, (2) the administration code (injection or infusion), and (3) the E&M visit. Most practices bill only the E&M, forfeiting the drug and administration revenue entirely.
Office visit for medication review, response assessment, side effects, and dosing decision
99214$218Octreotide acetate LAR 1mg (×30 for 30mg dose) — drug acquisition cost billed per mg
J2353 × 30$3,720Therapeutic intramuscular injection administration — separate from E&M and drug codes
96372$48Unused drug waste from single-use vials — JW modifier for Medicare waste billing
J2353 + JWVariableLong-acting somatostatin analogue for acromegaly and carcinoid syndrome. Administered monthly as deep gluteal IM injection. J-code billed per 1mg — a 20mg dose = J2353 × 20; 30mg dose = J2353 × 30. One of the highest-value J-codes in endocrinology, and the most commonly missed entirely by practices billing only the office visit.
Alternative long-acting somatostatin analogue for acromegaly and GEP-NETs. Administered monthly or every 4–8 weeks as deep subcutaneous injection. J0585 per 1mg — 60mg = J0585 × 60 ($1,840); 90mg = J0585 × 90 ($2,760); 120mg = J0585 × 120 ($3,680). Requires correct dose documentation in the procedure note to support the J-code quantity.
Annual IV bisphosphonate infusion for osteoporosis. 5mg dose administered as a 15-minute intravenous infusion. J3488 per 1mg — annual 5mg dose = J3488 × 5 ($680 drug). The infusion administration (96365, $128) generates additional revenue. Most practices administer Reclast annually and bill only an office visit code for the infusion day.
IM testosterone for male hypogonadism — typically 100–200mg every 1–2 weeks (cypionate, J1071) or 200–400mg every 2–4 weeks (enanthate, J3121). Each injection visit generates the drug J-code per mg + IM admin code + E&M visit. High-volume for practices managing hypogonadism — injection visits may be 2–4× monthly per patient.
Weekly subcutaneous GLP-1 receptor agonist for T2DM, when administered in-office. J0787 per 2mg dose. J-code billing applies only when the injection is administered in the physician's office. In-office GLP-1 initiation visit with supervised first injection is the most common in-office administration scenario generating J-code revenue.
Daily subcutaneous parathyroid hormone analogue for severe osteoporosis — typically self-administered but often initiated in-office with training. J3110 per 28.2mcg. When provided as samples or starter kits in the office, the physician billing is the administration code only. Requires careful documentation of sample vs. purchased stock.
These are not isolated errors. Each one is systematic — affecting the same encounter types, the same codes, the same documentation failures, across every billing cycle. All of them are correctable. None of them require seeing more patients.
The single largest revenue gap in endocrinology: injectable medications administered in-office generate drug J-codes that are billed entirely separately from the E&M visit. These are not included in the office visit payment. Not billing them means collecting only $105–$328 for an encounter that should generate $913–$3,986 in total charges.
CGM device supply billing (HCPCS A9276 sensors and A9278 receiver) is DME billing — submitted on a CMS-1450 claim form through a DME supplier number, not on the CMS-1500 physician claim form. Physician practices not billing DME supply codes lose this entire monthly recurring stream.
The most pervasive under-billing in endocrinology is E&M level selection — specifically the reflexive use of 99213 ($105) for all diabetes return visits when the clinical documentation consistently supports 99214 ($218) or 99215 ($328). At $110 additional per encounter × 100 patients × 4 visits/year = $44,000 annually from code level selection alone.
When an endocrinologist formally reviews and interprets a thyroid ultrasound — writing a separate interpretation and report — the professional interpretation component (76536-26) is separately billable at $98 per interpretation. Endocrinologists reading thyroid ultrasounds without generating a formal written report miss this billing entirely.
DSMES services delivered by a CDCES within a Medicare-recognized program are separately billable with G0108 (individual, 30 min, $72) and G0109 (group, $36). Most practices employing CDCESs for diabetes education do not bill G0108/G0109 at all — either because the practice is not enrolled in a DSMES program, or the billing team doesn't know the codes exist.
An ACTH stimulation test has multiple separately billable components: IV infusion of cosyntropin (96365), serial venipunctures (36415 × 3–4), timed cortisol labs (82533 × 3), and the E&M interpretation. When this entire testing day is submitted as a single 99215 ($328), the practice loses infusion, venipuncture, and lab components — typically $400–$510 per stimulation test encounter.
Using E11.9 (T2DM without complications) for every T2DM patient — including those with nephropathy, retinopathy, neuropathy — understates patient acuity, reduces documentation support for high-complexity E&M codes, and creates audit vulnerability when the physician's note documents complications but the claim shows none.
Every medication in endocrinology requires monitoring labs — and every monitoring lab ordered and interpreted by the endocrinologist is a separately billable code. From HbA1c for diabetes to IGF-1 for octreotide dosing to PTH for teriparatide response — the lab monitoring ecosystem generates substantial per-visit revenue when coded correctly.
Endocrinologists performing thyroid fine needle aspiration biopsies, interpreting thyroid ultrasounds, and ordering radioactive iodine studies are entitled to separately bill for each procedure component — the biopsy, the guidance technique, the interpretation, and cytopathology review. Most practices bill only the office visit code for these procedure-heavy encounters.
Fine needle aspiration of a thyroid nodule performed by palpation guidance — the endocrinologist identifies the nodule by palpation and performs the FNA with a fine needle and syringe. CPT 10021 covers the biopsy procedure. A thyroid FNA without imaging guidance encounter generates $132 in procedure revenue beyond the E&M visit.
Fine needle aspiration with real-time ultrasound imaging guidance — the endocrinologist uses ultrasound to visualize the needle in real time during the biopsy procedure. CPT 10022 covers the biopsy, and 76942 covers the ultrasound imaging guidance. Ultrasound-guided FNA generates $280 more than unguided FNA and is the standard of care for most thyroid nodules.
When the endocrinologist reviews and formally interprets a thyroid ultrasound — writing a separate interpretation report documenting findings, nodule characteristics, TIRADS classification, and clinical recommendations — the professional interpretation component (76536-26) is separately billable. This is the most commonly missed code in thyroid endocrinology.
CGM and insulin pump supply billing, injectable drug J-code management, hormone system lab panel coding, dynamic testing protocols, thyroid procedure billing, DSMES program billing, and E&M complexity optimization — all in one endocrinology billing partnership.
Every in-office injectable medication coded with the correct J-code, correct dose quantity, and correct administration code — submitted alongside the E&M visit on every encounter where an in-office drug is documented.
All CGM billing streams managed — physician-side codes (95249–95251), DME supply codes (A9276/A9278), and insulin pump management — submitted correctly on separate claim forms with complete documentation requirements.
Every lab ordered and interpreted by the endocrinologist coded individually — thyroid function panels, diabetes monitoring panels, bone metabolic panels, pituitary hormone panels, and adrenal axis labs all separately billed beyond the E&M.
FNA biopsy coding (guided and unguided), thyroid ultrasound professional interpretation (-26 modifier), radioactive iodine study billing, and nuclear medicine procedure coding — all procedure revenue captured beyond the office visit.
Every endocrinology encounter reviewed for correct E&M complexity level — diabetes encounters audited for MDM support of 99214/99215, dynamic testing days coded at complexity level supported by results interpretation and prescription management decisions.
G0108/G0109 diabetes education billing enrollment, CDCES credentialing for billing purposes, Medicare DSMES program compliance, and annual education hour tracking — education services already being delivered, now generating billed revenue.
The recoveries below didn't come from seeing more patients, billing harder, or coding more aggressively. They came from billing what was already being done — completely, correctly, for the first time.
"I have 22 acromegaly patients on monthly octreotide LAR 20mg or 30mg injections. My previous billing was 99214 per injection visit — $218 per month per patient. My total annual octreotide injection billing was $57,408. After ParaMed started billing J2353 with the correct dose quantities + 96372 + the office visit: our octreotide injection revenue became $1,082,016 annually. The same 22 patients. The same injections. The same work. One million dollars in previously unbilled drug revenue that I was entitled to collect and simply never captured."
"We have two CDCESs on staff who see 65 patients per month for individual diabetes education sessions — 30 minutes each. We were not billing G0108 at all. Our billing team didn't know the code existed. ParaMed's audit showed us that at $72 per G0108 × 65 sessions × 12 months, we were forfeiting $56,160 annually from education we were already delivering. Add to that the 78 patients whose CGM sensors we were providing but not billing the A9276 supply code: $184 × 78 × 12 = $171,936 in annual supply revenue. ParaMed recovered $228,096 annually from two billing gaps our previous team didn't know existed."
"I perform thyroid ultrasound interpretations for my own patients every week — reviewing the images, writing up the TIRADS classification, nodule measurements, and clinical recommendations. My previous biller said 'that's included in the office visit.' It is not. 76536-26 at $98 per interpretation × 55 interpretations per month = $5,390/month that ParaMed now bills that I was previously giving away for free. That's $64,680 per year. From writing the same ultrasound interpretation I was already writing anyway, just now with the correct code submitted alongside it."
The revenue gap in endocrinology isn't a volume problem. It's a billing completeness problem. Every in-office injectable you administer has a J-code. Every CGM you prescribe has supply billing. Every ultrasound you interpret has a professional component. Every lab panel you review has individual codes. A ParaMed audit finds every dollar in 30 days.
Every in-office injectable reviewed — octreotide, lanreotide, testosterone, zoledronic acid, teriparatide. Current J-code submission rate vs. correct billing calculated with annual revenue gap identified per drug.
Physician CGM codes (95249–95251) capture rate reviewed. DME supply billing (A9276/A9278) status confirmed. Monthly recurring supply revenue opportunity quantified per active CGM patient.
Current E&M level distribution reviewed against MDM complexity documentation. Lab interpretation billing rate assessed — every missed lab panel code identified and monetized.
Trusted by Practices Across US — Feedback from providers who rely on ParaMed for smarter Medical Billing.
